BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Selvaraj V, Finn A, Lal A, Khan MS, Dapaah-Afriyie K, Carino GP. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine 2022;49:101489. [PMID: 35677732 DOI: 10.1016/j.eclinm.2022.101489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Pasquereau S, Galais M, Bellefroid M, Pachón Angona I, Morot-bizot S, Ismaili L, Van Lint C, Herbein G. Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro. Sci Rep 2022;12:20309. [DOI: 10.1038/s41598-022-24682-9] [Reference Citation Analysis]
2 Mccarthy MW. Ensitrelvir as a potential treatment for COVID-19. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2146493] [Reference Citation Analysis]
3 Arbore DR, Galdean SM, Dima D, Rus I, Kegyes D, Ababei RG, Dragancea D, Tomai RA, Trifa AP, Tomuleasa C. COVID-19 Impact on Chronic Myeloid Leukemia Patients. JPM 2022;12:1886. [DOI: 10.3390/jpm12111886] [Reference Citation Analysis]
4 Cherian JJ, Eerike M, Bagepally BS, Das S, Panda S. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. Front Pharmacol 2022;13:1004308. [DOI: 10.3389/fphar.2022.1004308] [Reference Citation Analysis]
5 Sensen B, Wichmann D, Kluge S. Medikamentöse Therapiemaßnahmen bei akuter SARS-CoV-2-Infektion: wer, wann und was? Dtsch Med Wochenschr 2022;147:1313-1320. [DOI: 10.1055/a-1817-8872] [Reference Citation Analysis]
6 Subramaniam A, Tiruvoipati R, Pilcher D, Bailey M. Treatment limitations and clinical outcomes in critically ill frail patients with and without COVID-19 pneumonitis. J Am Geriatr Soc 2022. [PMID: 36151970 DOI: 10.1111/jgs.18044] [Reference Citation Analysis]
7 Selickman J, Vrettou CS, Mentzelopoulos SD, Marini JJ. COVID-19-Related ARDS: Key Mechanistic Features and Treatments. J Clin Med 2022;11:4896. [PMID: 36013135 DOI: 10.3390/jcm11164896] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Richardson PJ, Stebbing J. Baricitinib as the treatment of choice for hospitalised individuals with COVID-19. EClinicalMedicine 2022;49:101493. [PMID: 35692219 DOI: 10.1016/j.eclinm.2022.101493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Richardson PJ, Robinson BWS, Smith DP, Stebbing J. The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. Vaccines (Basel) 2022;10:951. [PMID: 35746559 DOI: 10.3390/vaccines10060951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]